Amgen (AMGN) Tops Q2 EPS by 32c, Reaffirms FY Guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.38, $0.32 better than the analyst estimate of $4.06. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.43 billion.

GUIDANCE:

Amgen sees 2021 EPS of $16.00-$17.00, versus the consensus of $16.34. Amgen sees 2021 revenue of $25.8-26.6 billion, versus the consensus of $26.04 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
• Dollar General (DG) Tops Q2 EPS by 48c, Beats on Revenue; Offers FY27 EPS Guidance